|
1
|
Daly AF, Jaffrain-Rea ML, Ciccarelli A, et
al: Clinical characterization of familial isolated pituitary
adenomas. J Clin Endocrinol Metab. 91:3316–3323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alexander JM, Biller BM, Bikkal H, Zervas
NT, Arnold A and Klibanski A: Clinically nonfunctioning pituitary
tumors are monoclonal in origin. J Clin Invest. 86:336–340. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shimon I and Melmed S: Genetic basis of
endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol
Metab. 82:1675–1681. 1997.PubMed/NCBI
|
|
4
|
Landis CA, Masters SB, Spada A, Pace AM,
Bourne HR and Vallar L: GTPase inhibiting mutations activate the
alpha chain of Gs and stimulate adenylyl cyclase in human pituitary
tumours. Nature. 340:692–696. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ogino A, Yoshino A, Katayama Y, Watanabe
T, et al: The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently
deregulated in human pituitary adenomas. J Neuropathol Exp Neurol.
64:398–403. 2005.PubMed/NCBI
|
|
8
|
Fombonne J, Devouassoux-Shisheboran M,
Bouvier R, Droz JP, Benahmed M and Krantic S: Analysis of p16INK4A
gene promoter in male germ-cell tumors: identification of a new
point mutation. Cancer Detect Prev. 29:1–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW
and Lui WY: Aberrant methylation of EDNRB and p16 genes in
hepatocellular carcinoma (HCC) in Taiwan. Oncol Rep. 15:507–511.
2006.PubMed/NCBI
|
|
10
|
Abbaszadegan MR, Raziee HR, Ghafarzadegan
K, Shakeri MT, Afsharnezhad S and Ghavamnasiry MR: Aberrant p16
methylation, a possible epigenetic risk factor in familial
esophageal squamous cell carcinoma. Int J Gastrointest Cancer.
36:47–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ono Y, Ueki K, Joseph JT and Louis DN:
Homozygous deletions of the CDKN2/p16 gene in dural
hemangiopericytomas. Acta Neuropathol. 91:221–225. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang SJ, Endo S, Ichikawa T, Washiyama K
and Kumanishi T: Frequent deletion and 5′ CpG island methylation of
the p16 gene in primary malignant lymphoma of the brain. Cancer
Res. 58:1231–1237. 1998.
|
|
13
|
Simpson DJ, Bicknell JE, McNicol AM,
Clayton RN and Farrell WE: Hypermethylation of the p16/CDKN2A/MTS1
gene and loss of protein expression is associated with
nonfunctional pituitary adenomas but not somatotrophinomas. Genes
Chromosomes Cancer. 24:328–336. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Seemann N, Kuhn D, Wrocklage C, et al:
CDKN2A/p16 inactivation is related to pituitary adenoma type and
size. J Pathol. 193:491–497. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farrell WE, Simpson DJ, Bicknell JE,
Talbot AJ, Bates AS and Clayton RN: Chromosome 9p deletions in
invasive and noninvasive nonfunctional pituitary adenomas: the
deleted region involves markers outside of the MTS1 and MTS2 genes.
Cancer Res. 57:2703–2709. 1997.PubMed/NCBI
|
|
16
|
Yoshimoto K, Tanaka C, Yamada S, et al:
Infrequent mutations of p16INK4A and p15INK4B genes in human
pituitary adenomas. Eur J Endocrinol. 136:74–80. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abd El-Moneim HM and Abd El-Rehim D:
Immunohistochemical and molecular study of p16INK4A expression in
pituitary adenoma. J Egypt Natl Canc Inst. 21:351–360.
2009.PubMed/NCBI
|
|
18
|
Sauroja I, Smeds J, Vlaykova T, Kumar R,
et al: Analysis of G(1)/S checkpoint regulators in metastatic
melanoma. Genes Chromosomes Cancer. 28:404–414. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCloud JM, Sivakumar R, Greenhough A, et
al: p16INK4apolymorphism: associations with tumour
progression in patients with sporadic colorectal cancer. Int J
Oncol. 25:1447–1452. 2004.
|
|
20
|
Yan L, Na W, Shan K, Xiao-Wei M, Wei G and
Shu-Cheng C: p16(CDKN2) gene polymorphism: association with
histologic subtypes of epithelial ovarian cancer in China. Int J
Gynecol Cancer. 18:30–35. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Simpson DJ, Fryer AA, Grossman AB, et al:
Cyclin D1 (CCND1) genotype is associated with tumour grade in
sporadic pituitary adenomas. Carcinogenesis. 22:1801–1807. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cottier JP, Destrieux C, Brunereau L, et
al: Cavernous sinus ınvasion by pituitary adenoma: MR imaging.
Radiology. 215:463–469. 2000.
|
|
23
|
Figarella-Branger D and Trouillas J: The
new WHO classification of human pituitary tumors: comments. Acta
Neuropathol. 111:71–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ono Y, Tamiya T, Ichikawa T, et al:
Malignant astrocytomas with homozygous CDKN2/p16 gene deletions
have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol.
55:1026–1031. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Biernat W, Tohma Y, Yonekawa Y, Kleihues P
and Ohgaki H: Alterations of cell cycle regulatory genes in primary
(de novo) and secondary glioblastomas. Acta Neuropathol.
94:303–309. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Woloschak M, Yu A, Xiao J and Post KD:
Frequent loss of the p16INK4a gene product in human pituitary
tumors. Cancer Res. 56:2493–2496. 1996.PubMed/NCBI
|
|
27
|
Woloschak M, Yu A and Post KD: Frequent
inactivation of the p16 gene in human pituitary tumors by gene
methylation. Mol Carcinog. 19:221–224. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaffrain-Rea ML, Ferretti E, Toniato E, et
al: p16 (INK4a, MTS-1) gene polymorphism and methylation status in
human pituitary tumours. Clin Endocrinol (Oxf). 51:317–325. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Machiavelli G, Cotignola J, Danilowicz K,
et al: Expression of p16(INK4A) gene in human pituitary tumours.
Pituitary. 11:71–75. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Geddert H, Kiel S, Zotz RB, et al:
Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the
upper gastrointestinal tract. J Cancer Res Clin Oncol. 131:803–808.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng Y, Shen H, Sturgis EM, et al:
Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and
risk of squamous cell carcinoma of the head and neck: a
case-control study. Cancer Epidemiol Biomarkers Prev. 11:640–645.
2002.
|
|
32
|
Thakur N, Hussain S, Nasare V, et al:
Association analysis of p16 (CDKN2A) and RB1 polymorphisms with
susceptibility to cervical cancer in Indian population. Mol Biol
Rep. 39:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen J, Li D, Wei C, et al: Aurora-A and
p16 polymorphisms contribute to an earlier age at diagnosis of
pancreatic cancer in Caucasians. Clin Cancer Res. 13:3100–3104.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Li D, Killary AM, et al:
Polymorphisms of p16, p27, p73, and MDM2 modulate response and
survival of pancreatic cancer patients treated with preoperative
chemoradiation. Ann Surg Oncol. 16:431–439. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chansaenroj J, Theamboonlers A,
Junyangdikul P, et al: Polymorphisms in TP53 (rs1042522), p16
(rs11515 and rs3088440) and NQO1 (rs1800566) genes in Thai cervical
cancer patients with HPV 16 infection. Asian Pac J Cancer Prev.
14:341–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tuna G, Küçükhüseyin O, Arıkan S, et al:
Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309
T>G gene variants act on colorectal cancer development or
progression? DNA Cell Biol. 32:400–408. 2013.
|
